A federal jury ruled that Apple must pay $634 million for infringing smartwatch patents.

In the subsequent and complicated event between the apple and Masimo, the latest decision from the California prison could be the first step towards a certain end. As reported by ReutersA federal jury has acquitted Masimo, a medical technology company known for its patient monitoring devices, in which it says Apple infringed on the company’s patent for technology that tracks blood levels of oxygen.

This lawsuit alleges that Apple infringed on Masimo’s patents related to blood-oxygen sensors, which the jury said can be seen through the Apple Watch workout and heart rate applications. In accordance with ReutersApple split the decision, adding that “one patent in this case expires in 2022, and is specific to patient monitoring technology from decades ago.” The tech giant is said to be planning to appeal this decision.

Although there may be a ban on this ability in California, Apple and Masimo are included in the web of related but different. Masimo First accused Apple of infringing its oximeter patents, leading to a temporary sales freeze on its 16 and Ultra 2 smartwatches. In August, Apple reorganized its blood monitoring feature and wrapped it in series 9, series 10 and Ultra 2. Redesnign is allowed by the agency to sell refurbished Apple watches without input from Masimo.